Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | MicrobiomeTrials← Back to trialsNCT07252726
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-02-02Est. Completion: 2027-03
Enrollment target: 50 participants Locations- Waterloo Regional Health Network, Kitchener, Ontario, Canada
- The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
- Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
Other microbiome trials you might be interested in
Breast CancerBreast CarcinomaCancer of the BreastMalignant Neoplasm of Breast
Background:
Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or bra…
Bethesda, United StatesEst. completion Jul 1, 2033
Breast Cancer Female
The study will explore the experiences of women going to see their GP with breast-related health concerns and will invol…
Nottingham, United KingdomCompleted Jan 31, 2026
Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination wi…
Birmingham, United StatesEst. completion Dec 30, 2027